320 related articles for article (PubMed ID: 18588507)
1. The selectivity of inhibitors of protein kinase CK2: an update.
Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
[TBL] [Abstract][Full Text] [Related]
2. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
[TBL] [Abstract][Full Text] [Related]
3. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.
Pagano MA; Meggio F; Ruzzene M; Andrzejewska M; Kazimierczuk Z; Pinna LA
Biochem Biophys Res Commun; 2004 Sep; 321(4):1040-4. PubMed ID: 15358133
[TBL] [Abstract][Full Text] [Related]
4. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
5. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
Leung KK; Shilton BH
Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
[TBL] [Abstract][Full Text] [Related]
6. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets.
Duncan JS; Gyenis L; Lenehan J; Bretner M; Graves LM; Haystead TA; Litchfield DW
Mol Cell Proteomics; 2008 Jun; 7(6):1077-88. PubMed ID: 18258654
[TBL] [Abstract][Full Text] [Related]
7. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
8. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.
Pagano MA; Andrzejewska M; Ruzzene M; Sarno S; Cesaro L; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Pinna LA
J Med Chem; 2004 Dec; 47(25):6239-47. PubMed ID: 15566294
[TBL] [Abstract][Full Text] [Related]
9. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
[TBL] [Abstract][Full Text] [Related]
10. Novel small molecule protein kinase CK2 inhibitors exert potent antitumor effects on T98G and SEGA cells in vitro.
Pucko E; Ostrowski R; Matyja E
Folia Neuropathol; 2019; 57(3):239-248. PubMed ID: 31588710
[TBL] [Abstract][Full Text] [Related]
11. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2.
Najda-Bernatowicz A; Łebska M; Orzeszko A; Kopańska K; Krzywińska E; Muszyńska G; Bretner M
Bioorg Med Chem; 2009 Feb; 17(4):1573-8. PubMed ID: 19168362
[TBL] [Abstract][Full Text] [Related]
13. DMAT, an inhibitor of protein kinase CK2 induces reactive oxygen species and DNA double strand breaks.
Schneider CC; Hessenauer A; Götz C; Montenarh M
Oncol Rep; 2009 Jun; 21(6):1593-7. PubMed ID: 19424641
[TBL] [Abstract][Full Text] [Related]
14. New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole.
Bretner M; Najda-Bernatowicz A; Łebska M; Muszyńska G; Kilanowicz A; Sapota A
Mol Cell Biochem; 2008 Sep; 316(1-2):87-9. PubMed ID: 18548199
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells.
Kaminska B; Ellert-Miklaszewska A; Oberbek A; Wisniewski P; Kaza B; Makowska M; Bretner M; Kazimierczuk Z
Int J Oncol; 2009 Nov; 35(5):1091-100. PubMed ID: 19787263
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity.
Łukowska-Chojnacka E; Wińska P; Wielechowska M; Poprzeczko M; Bretner M
Bioorg Med Chem; 2016 Feb; 24(4):735-41. PubMed ID: 26778657
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-leukemic effects of CK2 inhibitors and pentabromobenzylisothioureas in vitro.
Koronkiewicz M; Chilmonczyk Z; Kazimierczuk Z
Anticancer Res; 2013 Nov; 33(11):4891-9. PubMed ID: 24222126
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, in vitro antiproliferative activity and kinase profile of new benzimidazole and benzotriazole derivatives.
Chojnacki K; Wińska P; Skierka K; Wielechowska M; Bretner M
Bioorg Chem; 2017 Jun; 72():1-10. PubMed ID: 28340404
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
Sass G; Klinger N; Sirma H; Hashemolhosseini S; Hellerbrand C; Neureiter D; Wege H; Ocker M; Tiegs G
Int J Oncol; 2011 Aug; 39(2):433-42. PubMed ID: 21567083
[TBL] [Abstract][Full Text] [Related]
20. Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A.
Sarno S; Mazzorana M; Traynor R; Ruzzene M; Cozza G; Pagano MA; Meggio F; Zagotto G; Battistutta R; Pinna LA
Cell Mol Life Sci; 2012 Feb; 69(3):449-60. PubMed ID: 21720886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
